David H Murray1, Erin L Symonds2,3, Graeme P Young4, Susan Byrne4, Philippa Rabbitt5, Amitesh Roy6, Kathryn Cornthwaite4, Christos S Karapetis6, Susanne K Pedersen1. 1. Clinical Genomics Pty Ltd, North Ryde, NSW, Australia. 2. Flinders Centre for Innovation in Cancer, College of Medicine and Public Health, Flinders University of South Australia, Bedford Park, SA, 5042, Australia. erin.symonds@sa.gov.au. 3. Bowel Health Service, Flinders Medical Centre, Bedford Park, SA, Australia. erin.symonds@sa.gov.au. 4. Flinders Centre for Innovation in Cancer, College of Medicine and Public Health, Flinders University of South Australia, Bedford Park, SA, 5042, Australia. 5. Colorectal Surgery, Division of Surgery and Perioperative Medicine, Flinders Medical Centre, Bedford Park, SA, Australia. 6. Department of Oncology, Flinders Medical Centre, Bedford Park, SA, Australia.
Abstract
PURPOSE: Methylation in IKZF1 and BCAT1 are common events in colorectal cancer (CRC). They are often detected in blood as circulating tumor DNA (ctDNA) at diagnosis and disappear after surgery in most CRC patients. A prospective study was conducted to determine the relationship between detection of these markers following surgery and risk for residual disease and for recurrence. METHODS: ctDNA status with methylated BCAT1 and IKZF1 was determined within 12 months of surgical resection of CRC, and was related to presence of or risk for residual disease (margins involved, metastases present or nature of node involvement), and to recurrence-free survival. RESULTS: Blood was collected from 172 CRC patients after surgery and 28 (16%) were ctDNA positive. Recurrence was diagnosed in 23 of the 138 with clinical follow-up after surgery (median follow-up 23.3 months, IQR 14.3-29.5). Multivariate modeling indicated that features suggestive of residual disease were an independent predictor of post-surgery ctDNA status: cases with any of three features (close resection margins, apical node involved, or distant metastases) were 5.3 times (95% CI 1.5-18.4, p = 0.008) more likely to be ctDNA positive. Multivariate analysis showed that post-surgery ctDNA positivity was independently associated with an increased risk of recurrence (HR 3.8, 1.5-9.5, p = 0.004). CONCLUSIONS: CRC cases positive for methylated ctDNA after surgery are at increased risk of residual disease and subsequently recurrence. This could have implications for guiding recommendations for adjuvant therapy and surveillance strategies. Randomized studies are now indicated to determine if monitoring cases with these biomarkers leads to survival benefit.
PURPOSE: Methylation in IKZF1 and BCAT1 are common events in colorectal cancer (CRC). They are often detected in blood as circulating tumor DNA (ctDNA) at diagnosis and disappear after surgery in most CRC patients. A prospective study was conducted to determine the relationship between detection of these markers following surgery and risk for residual disease and for recurrence. METHODS: ctDNA status with methylated BCAT1 and IKZF1 was determined within 12 months of surgical resection of CRC, and was related to presence of or risk for residual disease (margins involved, metastases present or nature of node involvement), and to recurrence-free survival. RESULTS: Blood was collected from 172 CRC patients after surgery and 28 (16%) were ctDNA positive. Recurrence was diagnosed in 23 of the 138 with clinical follow-up after surgery (median follow-up 23.3 months, IQR 14.3-29.5). Multivariate modeling indicated that features suggestive of residual disease were an independent predictor of post-surgery ctDNA status: cases with any of three features (close resection margins, apical node involved, or distant metastases) were 5.3 times (95% CI 1.5-18.4, p = 0.008) more likely to be ctDNA positive. Multivariate analysis showed that post-surgery ctDNA positivity was independently associated with an increased risk of recurrence (HR 3.8, 1.5-9.5, p = 0.004). CONCLUSIONS: CRC cases positive for methylated ctDNA after surgery are at increased risk of residual disease and subsequently recurrence. This could have implications for guiding recommendations for adjuvant therapy and surveillance strategies. Randomized studies are now indicated to determine if monitoring cases with these biomarkers leads to survival benefit.
Entities:
Keywords:
Circulating tumor DNA (ctDNA); Colorectal cancer (CRC); Methylated DNA; Residual disease; Survival
Authors: Orbicia Riccio; Marielle E van Gijn; April C Bezdek; Luca Pellegrinet; Johan H van Es; Ursula Zimber-Strobl; Lothar J Strobl; Tasuku Honjo; Hans Clevers; Freddy Radtke Journal: EMBO Rep Date: 2008-02-15 Impact factor: 8.807
Authors: Biola M Javierre; Javier Rodriguez-Ubreva; Fatima Al-Shahrour; Marina Corominas; Osvaldo Graña; Laura Ciudad; Xabier Agirre; David G Pisano; Alfonso Valencia; Jose Roman-Gomez; Maria Jose Calasanz; Felipe Prosper; Manel Esteller; Rogelio Gonzalez-Sarmiento; Esteban Ballestar Journal: Mol Cancer Res Date: 2011-07-07 Impact factor: 5.852
Authors: Chetan Bettegowda; Mark Sausen; Rebecca J Leary; Isaac Kinde; Yuxuan Wang; Nishant Agrawal; Bjarne R Bartlett; Hao Wang; Brandon Luber; Rhoda M Alani; Emmanuel S Antonarakis; Nilofer S Azad; Alberto Bardelli; Henry Brem; John L Cameron; Clarence C Lee; Leslie A Fecher; Gary L Gallia; Peter Gibbs; Dung Le; Robert L Giuntoli; Michael Goggins; Michael D Hogarty; Matthias Holdhoff; Seung-Mo Hong; Yuchen Jiao; Hartmut H Juhl; Jenny J Kim; Giulia Siravegna; Daniel A Laheru; Calogero Lauricella; Michael Lim; Evan J Lipson; Suely Kazue Nagahashi Marie; George J Netto; Kelly S Oliner; Alessandro Olivi; Louise Olsson; Gregory J Riggins; Andrea Sartore-Bianchi; Kerstin Schmidt; le-Ming Shih; Sueli Mieko Oba-Shinjo; Salvatore Siena; Dan Theodorescu; Jeanne Tie; Timothy T Harkins; Silvio Veronese; Tian-Li Wang; Jon D Weingart; Christopher L Wolfgang; Laura D Wood; Dongmei Xing; Ralph H Hruban; Jian Wu; Peter J Allen; C Max Schmidt; Michael A Choti; Victor E Velculescu; Kenneth W Kinzler; Bert Vogelstein; Nickolas Papadopoulos; Luis A Diaz Journal: Sci Transl Med Date: 2014-02-19 Impact factor: 17.956
Authors: Frank Diehl; Kerstin Schmidt; Michael A Choti; Katharine Romans; Steven Goodman; Meng Li; Katherine Thornton; Nishant Agrawal; Lori Sokoll; Steve A Szabo; Kenneth W Kinzler; Bert Vogelstein; Luis A Diaz Journal: Nat Med Date: 2007-07-31 Impact factor: 53.440
Authors: Sébastien Malinge; Clarisse Thiollier; Timothy M Chlon; Louis C Doré; Lauren Diebold; Olivier Bluteau; Vinciane Mabialah; William Vainchenker; Philippe Dessen; Susan Winandy; Thomas Mercher; John D Crispino Journal: Blood Date: 2013-01-18 Impact factor: 22.113
Authors: Hak-Mien Quah; Joanne F Chou; Mithat Gonen; Jinru Shia; Deborah Schrag; Ron G Landmann; José G Guillem; Philip B Paty; Larissa K Temple; W Douglas Wong; Martin R Weiser Journal: Dis Colon Rectum Date: 2008-03-06 Impact factor: 4.585
Authors: Patrick S Ward; Jay Patel; David R Wise; Omar Abdel-Wahab; Bryson D Bennett; Hilary A Coller; Justin R Cross; Valeria R Fantin; Cyrus V Hedvat; Alexander E Perl; Joshua D Rabinowitz; Martin Carroll; Shinsan M Su; Kim A Sharp; Ross L Levine; Craig B Thompson Journal: Cancer Cell Date: 2010-02-18 Impact factor: 38.585
Authors: Susanne K Pedersen; Erin L Symonds; Rohan T Baker; David H Murray; Aidan McEvoy; Sascha C Van Doorn; Marco W Mundt; Stephen R Cole; Geetha Gopalsamy; Dileep Mangira; Lawrence C LaPointe; Evelien Dekker; Graeme P Young Journal: BMC Cancer Date: 2015-10-06 Impact factor: 4.430
Authors: Erin L Symonds; Susanne K Pedersen; Bernita Yeo; Hiba Al Naji; Susan E Byrne; Amitesh Roy; Graeme P Young Journal: Mol Oncol Date: 2022-01-24 Impact factor: 7.449
Authors: Warwick J Locke; Dominic Guanzon; Chenkai Ma; Yi Jin Liew; Konsta R Duesing; Kim Y C Fung; Jason P Ross Journal: Front Genet Date: 2019-11-14 Impact factor: 4.599
Authors: Teoman Deger; Ruben G Boers; Joost Gribnau; Saskia M Wilting; Vanja de Weerd; Lindsay Angus; Marjolijn M J van der Put; Joachim B Boers; Z Azmani; Wilfred F J van IJcken; Dirk J Grünhagen; Lisanne F van Dessel; Martijn P J K Lolkema; Cornelis Verhoef; Stefan Sleijfer; John W M Martens Journal: Clin Epigenetics Date: 2021-10-20 Impact factor: 6.551
Authors: Hao Xie; Douglas W Mahoney; Patrick H Foote; Kelli N Burger; Karen A Doering; William R Taylor; Sara S Then; Xiaoming Cao; Maria McGlinch; Calise K Berger; Tsung-Teh Wu; Joleen M Hubbard; Hatim T Allawi; Michael W Kaiser; Graham P Lidgard; David A Ahlquist; John B Kisiel Journal: Clin Cancer Res Date: 2020-10-07 Impact factor: 13.801